Continuing Medical Education Information: New Drugs in Oncology
General Accreditation Information
The American Society of Clinical Oncology (ASCO) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This live activity has been approved for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All nonphysician attendees are welcome to submit a request for a Certificate of Participation, through the submission of the evaluation form, which may enable nonphysicians to apply their Annual Meeting participation toward re-licensure. Specific nursing and pharmacy continuing education credit is no longer offered.
Any questions related to CME may be directed to ASCO Staff at email@example.com or 571-483-1403.
With emerging educational and scientific advances, oncology is a field where patient care standards can change very quickly. Due to the high volume of literature and best practices information available, it is important that oncologists and other cancer care providers synthesize and digest the latest evidence based information applicable to their practice/research setting.
In an effort to meet educational needs based on this rapid exchange of information, ASCO is committed to disseminating new information pertaining to drug development and its use.
This seminar is designed for physicians and researchers involved in drug development and patient care, including but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists.
The seminar may also be of benefit to nurses, pharmacists, physician assistants, and other health care professionals involved in clinical care and research in this area.
Upon participation in this activity, attendees will be able to:
- Examine new designs for phase I trials that serve to further enhance knowledge of drug efficacy, including ways to reduce cost and time of new drug development in order to improve patient outcomes
- Identify and evaluate the mechanisms of action, pharmacology, and adverse events associated with recently approved drugs in the oncology field
- Discuss ways in which drug development will be affected by the emerging concepts of drug safety in oncology
- Compare recently approved oncologic agents with those currently utilized in the patient care setting and determine the best option based on current evidence
This activity was planned in the context of the following ACGME competencies: Patient Care, Medical Knowledge, and Systems-based Practice.
Unlabelled Usage Statement
The information presented is that of the contributing faculty and does not necessarily represent the views of the American Society of Clinical Oncology and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.